Extrapulmonary neuroendocrine carcinoma (ep-nec)
Clinical trials for Extrapulmonary neuroendocrine carcinoma (ep-nec) explained in plain language.
Never miss a new study
Get alerted when new Extrapulmonary neuroendocrine carcinoma (ep-nec) trials appear
Sign up with your email to follow new studies for Extrapulmonary neuroendocrine carcinoma (ep-nec), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase 1/2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells carrying a protein called DLL3, found in small cell lung cancer and other solid tumors. The trial enrolls 138 adults whose cancer has progressed after at least two prior treatments. The goal is to check …
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase 1/2 • Sponsor: Molecular Partners AG • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail therapy targets rare cancer after standard treatment fails
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs—chidamide, sintilimab, and bevacizumab—in 34 people with advanced extrapulmonary neuroendocrine carcinoma that has worsened after first-line therapy. The goal is to see if this combo can shrink tumors or slow disease progressi…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC)
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC